BRPI0820131A2 - Derivados de oxadiazol ativos em esfingosina-1-fosfato (s1p) - Google Patents

Derivados de oxadiazol ativos em esfingosina-1-fosfato (s1p)

Info

Publication number: BRPI0820131A2
Authority: BR; Brazil
Prior art keywords: sphingosine; oxadiazole derivatives; phosphate active; phosphate; active
Prior art date: 2007-12-21

Application number

Other languages

English (en)

Inventor

Jag Paul Heer

Ian David Wall

Thomas Daniel Heightman

David Nigel Hurst

Christopher Norbert Johnson

Emmanuel Hubert Demont

Jason Witherington

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-12-21

Filing date

2008-12-19

Publication date

2015-05-12

2007-12-21 Priority claimed from GB0725120A external-priority patent/GB0725120D0/en

2008-12-01 Priority claimed from GB0821918A external-priority patent/GB0821918D0/en

2008-12-19 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2015-05-12 Publication of BRPI0820131A2 publication Critical patent/BRPI0820131A2/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Oncology (AREA)
Obesity (AREA)
Neurosurgery (AREA)
Endocrinology (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Transplantation (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Emergency Medicine (AREA)
Virology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Communicable Diseases (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

BRPI0820131 2007-12-21 2008-12-19 Derivados de oxadiazol ativos em esfingosina-1-fosfato (s1p) BRPI0820131A2 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB0725120A GB0725120D0 (en)	2007-12-21	2007-12-21	Compounds
GB0821918A GB0821918D0 (en)	2008-12-01	2008-12-01	Compounds
PCT/EP2008/067965 WO2009080725A1 (en)	2007-12-21	2008-12-19	Oxadiazole derivatives active on sphingosine-1-phosphate (sip)

Publications (1)

Publication Number	Publication Date
BRPI0820131A2 true BRPI0820131A2 (pt)	2015-05-12

Family

ID=40342566

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0820131 BRPI0820131A2 (pt)	2007-12-21	2008-12-19	Derivados de oxadiazol ativos em esfingosina-1-fosfato (s1p)

Country Status (28)

Country	Link
US (2)	US8222245B2 (pt)
EP (1)	EP2222669B1 (pt)
JP (1)	JP2011506569A (pt)
KR (1)	KR20100108566A (pt)
CN (1)	CN101945863B (pt)
AR (1)	AR069916A1 (pt)
AU (1)	AU2008339988B2 (pt)
BR (1)	BRPI0820131A2 (pt)
CA (1)	CA2710130A1 (pt)
CO (1)	CO6290646A2 (pt)
CR (1)	CR11579A (pt)
DK (1)	DK2222669T3 (pt)
DO (1)	DOP2010000194A (pt)
EA (1)	EA017691B1 (pt)
ES (1)	ES2434730T3 (pt)
HR (1)	HRP20130957T1 (pt)
IL (1)	IL206235A0 (pt)
MA (1)	MA31924B1 (pt)
NZ (1)	NZ585996A (pt)
PE (1)	PE20091339A1 (pt)
PL (1)	PL2222669T3 (pt)
PT (1)	PT2222669E (pt)
RS (1)	RS53038B (pt)
SI (1)	SI2222669T1 (pt)
TW (1)	TWI415847B (pt)
UY (1)	UY31570A1 (pt)
WO (1)	WO2009080725A1 (pt)
ZA (1)	ZA201003963B (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE102007026341A1 (de)	2007-06-06	2008-12-11	Merck Patent Gmbh	Benzoxazolonderivate
DE102007032507A1 (de)	2007-07-12	2009-04-02	Merck Patent Gmbh	Pyridazinonderivate
PE20091057A1 (es)	2007-12-19	2009-07-20	Lilly Co Eli	Antagonistas del receptor mineralcorticoide y metodos de uso
GB0725101D0 (en)	2007-12-21	2008-01-30	Glaxo Group Ltd	Compounds
GB0725105D0 (en)	2007-12-21	2008-01-30	Glaxo Group Ltd	Compounds
GB0725102D0 (en) *	2007-12-21	2008-01-30	Glaxo Group Ltd	Compounds
DE102007061963A1 (de)	2007-12-21	2009-06-25	Merck Patent Gmbh	Pyridazinonderivate
DE102008019907A1 (de)	2008-04-21	2009-10-22	Merck Patent Gmbh	Pyridazinonderivate
GB0807910D0 (en)	2008-04-30	2008-06-04	Glaxo Group Ltd	Compounds
DE102008028905A1 (de)	2008-06-18	2009-12-24	Merck Patent Gmbh	3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
MX2011006682A (es)	2008-12-22	2011-07-13	Merck Patent Gmbh	Nuevas formas polimorficas de dihidrogeno-fosfato de 6-(1-metil-1h-pirazol-4-il)-2-{3-[5-(2-morfolin-4-il-etoxi)-pirim idin-2-il]-bencil}-2h-piridazin-3-ona y procesos para su preparacion.
GB0910674D0 (en)	2009-06-19	2009-08-05	Glaxo Group Ltd	Novel compounds
WO2011028927A1 (en) *	2009-09-04	2011-03-10	Allergan, Inc.	Selective sphingosine-1-phosphate receptor antagonists
AU2012253653A1 (en)	2011-05-10	2013-05-02	Gilead Sciences, Inc.	Fused heterocyclic compounds as sodium channel modulators
CN102250035A (zh) *	2011-06-10	2011-11-23	北京富卡生物技术有限公司	二芳基取代-1，3，4-噁二唑化合物的合成方法和其药物用途
NO3175985T3 (pt)	2011-07-01	2018-04-28
TWI622583B (zh)	2011-07-01	2018-05-01	基利科學股份有限公司	作為離子通道調節劑之稠合雜環化合物
RU2543485C2 (ru) *	2013-02-26	2015-03-10	Андрей Александрович Иващенко	Гетероциклические агонисты рецепторов желчных кислот tgr5, фармацевтическая композиция, способы их получения и применения
CN104844535A (zh) *	2014-02-13	2015-08-19	吉利德科学公司	用于制备稠合杂环离子通道调节剂的方法
AR101591A1 (es)	2014-08-20	2016-12-28	Bristol Myers Squibb Co	Compuestos bicíclicos sustituidos
US10183940B2 (en) *	2014-11-14	2019-01-22	Boehringer Ingelheim International Gmbh	Aryl and heteroaryl-fused tetrahydro-1,4-oxazepine amides as somatostatin receptor subtype 4 (SSTR4) agonists
EP3227263B1 (en) *	2014-12-01	2019-04-10	Idorsia Pharmaceuticals Ltd	Cxcr7 receptor modulators
CA3066423A1 (en) *	2017-06-14	2018-12-20	Trevena, Inc.	Compounds for modulating s1p1 activity and methods of using the same
KR20230154194A (ko) *	2021-02-10	2023-11-07	이칸 스쿨 오브 메디슨 엣 마운트 시나이	신장 섬유증의 치료를 위한 HIPK2의 옥사디아졸릴 디하이드로피라노[2,3-b]피리딘 억제제
WO2023081328A1 (en) *	2021-11-04	2023-05-11	Valo Health, Inc.	Histone deacetylase 6 inhibitor compounds and uses thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP3964478B2 (ja)	1995-06-30	2007-08-22	エーザイ・アール・アンド・ディー・マネジメント株式会社	ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬
JPH1180026A (ja)	1997-09-02	1999-03-23	Yoshitomi Pharmaceut Ind Ltd	新規免疫抑制剤、その使用方法およびその同定方法
CN1254474C (zh)	2000-11-14	2006-05-03	史密斯克莱·比奇曼公司	作为多巴胺D<sub>3</sub>受体调节剂(精神抑制药)的四氢苯并氮杂䓬衍生物
JP2005533058A (ja)	2002-06-17	2005-11-04	メルク　エンド　カムパニー　インコーポレーテッド	Ｅｄｇ受容体アゴニストとしての１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）アゼチジン−３−カルボキシラートおよび１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）ピロリジン−３−カルボキシラート
WO2004113330A1 (en)	2003-05-19	2004-12-29	Irm Llc	Immunosuppressant compounds and compositions
CN1859908A (zh) *	2003-10-01	2006-11-08	默克公司	作为s1p受体激动剂的3,5－芳基、杂芳基或环烷基取代的－1,2,4－噁二唑类化合物
AU2004299456B2 (en)	2003-12-17	2010-10-07	Merck Sharp & Dohme Corp.	(3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists
JP5315611B2 (ja) *	2004-06-23	2013-10-16	小野薬品工業株式会社	Ｓ１ｐ受容体結合能を有する化合物およびその用途
GB0414795D0 (en)	2004-07-01	2004-08-04	Glaxo Group Ltd	Compounds
JP2008517915A (ja)	2004-10-22	2008-05-29	メルクエンドカムパニーインコーポレーテッド	Ｓ１ｐ受容体アゴニストとしての２−（アリール）アザシクリルメチルカルボキシレート、スルホネート、ホスホネート、ホスフィネート及びヘテロ環
JP4318087B2 (ja)	2004-12-13	2009-08-19	小野薬品工業株式会社	アミノカルボン酸誘導体およびその医薬用途
AU2006226018B2 (en) *	2005-03-23	2012-07-12	Idorsia Pharmaceuticals Ltd	Hydrogenated benzo (C) thiophene derivatives as immunomodulators
BRPI0609668A2 (pt)	2005-03-23	2011-10-18	Actelion Pharmaceuticals Ltd	composto, composição farmacêutica, e, uso de um composto
CN101203512A (zh) *	2005-04-22	2008-06-18	第一三共株式会社	杂环化合物
JP2008545767A (ja)	2005-06-08	2008-12-18	ノバルティスアクチエンゲゼルシャフト	多環式オキサジアゾールまたはイソキサゾールおよびｓｉｐ受容体リガンドとしてのそれらの使用
JP2009506046A (ja)	2005-08-23	2009-02-12	アイアールエム・リミテッド・ライアビリティ・カンパニー	免疫抑制剤化合物および組成物
TW200738694A (en)	2005-11-24	2007-10-16	Glaxo Group Ltd	Chemical compounds
MX2008012738A (es) *	2006-04-03	2009-02-06	Astellas Pharma Inc	Heterocompuesto.
WO2008064337A2 (en) *	2006-11-21	2008-05-29	University Of Virginia Patent Foundation	Benzocycloheptyl analogs having sphingosine 1-phosphate receptor activity
GB0725102D0 (en)	2007-12-21	2008-01-30	Glaxo Group Ltd	Compounds
GB0725101D0 (en)	2007-12-21	2008-01-30	Glaxo Group Ltd	Compounds
GB0725104D0 (en)	2007-12-21	2008-01-30	Glaxo Group Ltd	Compounds
GB0725105D0 (en)	2007-12-21	2008-01-30	Glaxo Group Ltd	Compounds

2008
- 2008-12-18 PE PE2008002122A patent/PE20091339A1/es not_active Application Discontinuation
- 2008-12-19 CN CN2008801273456A patent/CN101945863B/zh not_active Expired - Fee Related
- 2008-12-19 PL PL08864021T patent/PL2222669T3/pl unknown
- 2008-12-19 EP EP08864021.4A patent/EP2222669B1/en active Active
- 2008-12-19 BR BRPI0820131 patent/BRPI0820131A2/pt not_active IP Right Cessation
- 2008-12-19 TW TW097149553A patent/TWI415847B/zh not_active IP Right Cessation
- 2008-12-19 SI SI200831050T patent/SI2222669T1/sl unknown
- 2008-12-19 UY UY31570A patent/UY31570A1/es unknown
- 2008-12-19 KR KR1020107016167A patent/KR20100108566A/ko not_active Ceased
- 2008-12-19 HR HRP20130957AT patent/HRP20130957T1/hr unknown
- 2008-12-19 US US12/747,205 patent/US8222245B2/en not_active Expired - Fee Related
- 2008-12-19 WO PCT/EP2008/067965 patent/WO2009080725A1/en not_active Ceased
- 2008-12-19 JP JP2010538741A patent/JP2011506569A/ja active Pending
- 2008-12-19 AU AU2008339988A patent/AU2008339988B2/en not_active Expired - Fee Related
- 2008-12-19 ES ES08864021T patent/ES2434730T3/es active Active
- 2008-12-19 PT PT88640214T patent/PT2222669E/pt unknown
- 2008-12-19 AR ARP080105590A patent/AR069916A1/es not_active Application Discontinuation
- 2008-12-19 DK DK08864021.4T patent/DK2222669T3/da active
- 2008-12-19 EA EA201070782A patent/EA017691B1/ru not_active IP Right Cessation
- 2008-12-19 NZ NZ585996A patent/NZ585996A/en not_active IP Right Cessation
- 2008-12-19 CA CA2710130A patent/CA2710130A1/en not_active Abandoned
- 2008-12-19 RS RS20130479A patent/RS53038B/sr unknown
2009
- 2009-01-28 US US12/360,886 patent/US20100174065A1/en not_active Abandoned
2010
- 2010-06-03 ZA ZA2010/03963A patent/ZA201003963B/en unknown
- 2010-06-07 IL IL206235A patent/IL206235A0/en unknown
- 2010-06-16 MA MA32926A patent/MA31924B1/fr unknown
- 2010-06-21 CO CO10074455A patent/CO6290646A2/es active IP Right Grant
- 2010-06-21 DO DO2010000194A patent/DOP2010000194A/es unknown
- 2010-07-21 CR CR11579A patent/CR11579A/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
RS53038B (sr)	2014-04-30
KR20100108566A (ko)	2010-10-07
PL2222669T3 (pl)	2014-01-31
EP2222669B1 (en)	2013-08-21
US8222245B2 (en)	2012-07-17
PE20091339A1 (es)	2009-09-26
TW200940531A (en)	2009-10-01
HK1142062A1 (en)	2010-11-26
CN101945863B (zh)	2013-07-03
CA2710130A1 (en)	2009-07-02
PT2222669E (pt)	2013-10-28
MA31924B1 (fr)	2010-12-01
EP2222669A1 (en)	2010-09-01
US20100273771A1 (en)	2010-10-28
US20100174065A1 (en)	2010-07-08
TWI415847B (zh)	2013-11-21
CO6290646A2 (es)	2011-06-20
AU2008339988B2 (en)	2013-09-26
AU2008339988A1 (en)	2009-07-02
AR069916A1 (es)	2010-03-03
CR11579A (es)	2010-09-03
ES2434730T3 (es)	2013-12-17
EA201070782A1 (ru)	2010-12-30
NZ585996A (en)	2012-06-29
JP2011506569A (ja)	2011-03-03
DK2222669T3 (da)	2013-10-28
IL206235A0 (en)	2010-12-30
DOP2010000194A (es)	2010-08-15
ZA201003963B (en)	2011-11-30
EA017691B1 (ru)	2013-02-28
HRP20130957T1 (hr)	2013-11-08
UY31570A1 (es)	2009-05-29
SI2222669T1 (sl)	2013-10-30
CN101945863A (zh)	2011-01-12
WO2009080725A1 (en)	2009-07-02

Publication	Publication Date	Title
IL206235A0 (en)	2010-12-30	Oxadiazole derivatives active on sphingosine-1-phosphate (s1p)
CY2025012I1 (el)	2026-02-25	Δοσολογικο σχημα για εναν αγωνιστη των υποδοχεων s1p
BRPI0818457A2 (pt)	2015-04-14	Derivados de oxadiazol
CY2018004I2 (el)	2018-09-05	Συνδυαστικη θεραπεια υποκατεστημενης oξαζολιδινονης
DE602008005285D1 (de)	2011-04-14	Oxadiazolsubstituierte indazolderivate zur verwendung als sphingosin-1-phosphat (s1p) -agonisten
PT2003132E (pt)	2014-05-26	Derivados de oxadiazole como agonistas dos s1p1
DK2300013T4 (da)	2025-02-03	Phosphorderivater som kinasehæmmere
BRPI1013422A2 (pt)	2016-04-05	derivados de oxadiazol
IL206278A0 (en)	2010-12-30	Oxadiazole derivatives active on sphingosine-1-phosphate (s1p)
DK2021335T3 (da)	2011-09-05	Heterocykliske forbindelser som C-FMS-kinasehæmmere
DK2300459T3 (da)	2013-09-02	Nye fenylpyrazinoner som kinasehæmmere
DK2152712T3 (da)	2012-03-26	Aminoheterocykliske fobindelser
BRPI0818161A2 (pt)	2017-05-16	composições que compreendem moduladores de receptores de esfingosina-1-fosfato (s1p)
ZA200907045B (en)	2011-06-29	Insecticidal aryl isoxazoline derivatives
DK2206710T3 (da)	2012-08-27	Indolderivater som s1p1-receptor agonister
BRPI0922464A2 (pt)	2015-08-11	Combinações de compostos ativos
DK2308869T3 (da)	2012-10-08	Azolforbindelse
BRPI0906705A2 (pt)	2015-06-30	Composto heterocíclicos
DE112007001970A5 (de)	2009-05-28	Maschinengehäuse einer elektrischen Maschine
DE112007001996A5 (de)	2009-05-28	Maschinengehäuse einer elektrischen Maschine
FIU20100142U0 (fi)	2010-03-24	Järjestely virran muodostamiseksi
DE502007003492D1 (de)	2010-06-02	Zylindrische Wirkladung
HRP20150932T1 (xx)	2015-10-09	Heterocikliäśki spojevi
BR112013013648A2 (pt)	2016-09-06	derivados de fenil oxadiazol como moduladores de receptor de esfingosina-1-fosfato(s1p)
BRPI0820831A2 (pt)	2014-12-23	Combinações de composto ativo

Legal Events

Date	Code	Title	Description
2015-12-01	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 7A ANUIDADE.
2016-03-29	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.